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Abstract: Deglycosylated vitamin D-binding protein-derived
macrophage-activating factor (GcMAF) is known to be a strong
immune stimulatory natural molecule. Data in literature
demonstrate that GcMAF has a direct role in decreasing cell
proliferation of different cancer cell lines. In this study we
evaluate the direct effect of GcMAF complexed with oleic acid
(OA-GcMAF) on human multiple myeloma cells (KMS-12-
BM), as well as the effect on the same cell line of human
macrophages (CRL9853) previously activated by OA-GcMAF.
Cell viability and living cell number were evaluated
respectively by tetrazolium dye cell viability assay and by
Trypan blue staining. Interactions between activated
macrophages and myeloma cells were studied by time lapse
photography. Our results show that OA-GcMAF decreases the
cell viability of KMS-12-BM with a dose-dependent pathway.
Furthermore OA-GcMAF activates human macrophages, which
in turn phagocytise myeloma cancer cells. OA-GcMAF
confirms its double effect on cancer cells: a direct inhibition of
their viability and, at the same time, an efficient macrophage
activation leading to a significant depletion of cancer cell
population. Introduction: In recent years the interest of vitamin
D-binding protein-derived macrophage-activating factor
(GcMAF) as a potent immunotherapeutic agent has increased.
The GcMAF has been shown to be effective in stimulating
murine macrophages in vitro to phagocytose human breast
carcinoma cultures (1, 2), as well as inhibiting the growth of
prostate cancer cells (3). It has also been the agent that has
been referenced as reducing tumour burden in several clinical
approaches (4, 5). In previous studies GcMAF has been used to
stimulate Raw 264.7 cells (murine macrophage cell line) that
were observed in vitro to phagacytose MCF-7 cells (human
breast carcinoma). In this study we demonstrate the effect of
GcMAF stabilized with oleic acid (OA-GcMAF) directly on
KMS-12-BM multiple myeloma cells and on co-culture of
stimulated human macrophages (CRL9853) and KMS-12-BM.
Materials and Methods: Cell lines: KMS-12-BM: human
multiple myeloma cell line was purchased from DSMZ
(German Collection of Microorganisms and Cell Cultures,
Braunschweig, Germany) and cultured in RPMI 1640
supplemented with 10% FBS and 2mM L-Glutamine (Life
Technologies, Paisley, UK). Cultures were passaged every 3-4
days. CRL9853: human spleen macrophage was purchased
from ATCC (American Type Culture Collection, Teddington,
UK) and routinely cultured in IMDM supplemented with 10%
FBS and 2mM L-Glutamine (Life Technologies). Cultures
were passaged every 3-4 days. Prior to assay, CRL9853 cells
were activated culturing them for 72h in the presence of OA-
GcMAF at a concentration 100ng/ml in complete medium.
Stimuli: OA-GcMAF, commercially available, was prepared at
Immuno Biotech Ltd. (Guernsey, Channel Island) with a
proprietary procedure previously described (6). Cell viability
Abstracts of the 9th International Conference of Anticancer Research, 6-10 October 2014, Porto Carras, Sithonia, Greece
6175
Figure 1. KMS-12-BM cell viability assay and Trypan Blue viable cell counts. (A) Results for (8 pM) demonstrate a slight
decrease on cell proliferation which becomes significantly greater at (800 pM) indicating a direct effect on cell viability. (B) The
decrease in viable cell number as the OA-GcMAF concentration increases corroborating the observed cell viability assay data.
Results are expressed as mean value±S.E.M. for five replicates. (*p<0.01). 
assay: Cell viability was evaluated by the reduction of a
tetrazolium salt (WST-8) as an index of cell dehydrogenases’
activity. KMS-12-BM cells were seeded into a 96-well plate at
a density of 3x104 cells/well in their appropriate starvation
medium (without FBS). After incubation for 24h the cell line
was treated for 24h with the following different concentrations
of OA-GcMAF ([8-80-800 pM). At the end of the treatment,
the medium was replaced with 100μl of fresh starvation
medium plus 10μl of WST-8. The 96-well plate was incubated
for 3h at 37˚C and the optical density (O.D.) was directly
measured at A450nm by Multiscan FC photometer
(ThermoScientific, Milano, Italy). Cell counting – Trypan blue
assay: To corroborate the results obtained by cell viability
assay, a viable cell count was performed. Briefly, KMS-12-BM
cells were plated into a 6-well plate at a density of 2x105
cells/well in starvation medium. After 24h incubation, human
multiple myeloma cells were treated with OA-GcMAF at the
increasing concentrations (8-80-800 pM) for 24h. At the end
of the treatment, a volume of cell suspension was collected and
the viable cell number was counted by Trypan Blue staining.
Video-time lapse photography: KMS-12-BM cells were seeded
into a 24-well plate at a density of 1x106 cells/well with a 1ml
volume. The cells were allowed to settle for a minimum of 2h
prior to the addition of the OA-GcMAF-activated CRL9853
macrophages. The staging mat was set at a temperature of 37˚C
and allowed to equilibrate prior to placement of the 24-well
plate. The OA-GcMAF-activated CRL9853 macrophages were
added to a final concentration of 5x105 cells per well in 1ml.
HEPES (Fisher Scientific, Loughborough, UK) was added to
each well to provide a final concentration of 25mM to stabilize
the culture pH. Once activated macrophages and the HEPES
were added, the 24-well plate was observed microscopically
and an image selected. An initial frame was taken and a time-
lapse film initiated. A frame was taken every 3 minutes until
filming was stopped. Results: Cell viability assay: Cell viability
(Figure 1), evaluated both by tetrazolium dye cell assay (A)
and by Trypan blue staining (B), decreased when KMS-12-BM
cells were treated with increasing concentrations of OA-
GcMAF. In particular, when cells were treated with OA-
GcMAF (800 pM) a significant reduction (p<0.01) in cell
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Figure 2. Selected frame shots over time of KMS-12-BM cells in the presence of OA-GCMAF-stimulated CRL9853 human
macrophages. (A) KMS-12-BM suspension culture typical growth pattern. (B) KMS-12-BM cells 24h post addition of OA-GcMAF
activated human macrophages. CRL9853 cultures as large masses of suspension cells and the dense collection of cells can be
observed sitting on the KMS-12-BM suspension cells. The OA-GcMAF-activated macrophages are extremely motile under
observation and move around clearing the KMS-12-BM cells. During the phagocytosis smaller dense “clusters” of cells break
off and scavenge the KMS-12-BM cells quite rapidly. (C) KMS-12-BM cells 48h post addition of OA-GcMAF-activated human
macrophages. CRL9853 cells now have a few large cell mass “clusters” and many smaller “clusters” as can be observed (red
arrows). The number of KMS-12-BM cells has been decreased and the clearance of cells can be easily observed. (D) KMS-12-
BM cells 72h post addition of OA-GcMAF-activated human macrophages CRL9853. OA-GcMAF-activated CRL9853 cells are
still extremely active with the phagocytotic activity and are clearing the KMS-12-BM cells from the culture. This image shows
the smaller clusters of cells as indicated by the red arrows. The clusters have become smaller and rapid moving seeking out and
destroying the remaining KMS-12-BM cells. 
viability was observed in comparison to the untreated control
cells. Discussion: It has been shown that Gc-MAF activates
Raw 264.7 murine macrophages to phagocytose and destroy
MCF-7 human breast carcinoma cells (1). An identical effect
has been recorded for the first time with the stimulation of
human macrophages CRL9853 on KMS-12-BM cell line . The
OA-GcMAF-stimulated human macrophages seek out surround
and phagocytose the myeloma cell lines destroying them. This
demonstrates that the CRL9853 behave as postulated against
KMS-12- BM cell line. In addition the effect of increased cell
death in the presence of OA-GcMAF alone as indicated by
direct evaluation of viable cell counts and viability assay also
provides supports to the previous data generated (1). This
study provides some inferred evidence to support the in vivo
clinical data that has recently been published (6) providing
some insight into the method of potential tumour removal by
stimulated macrophages. In conclusion OA-GcMAF has
demonstrated two major effects: a direct decrease of KMS-12-
BM cell viability and an efficient activation of human
macrophages, which become able to phagocytose and destroy
the myeloma cells. The studies will be expanded further to
encompass additional cancer cell lines. 
1 Pacini S et al: Effects of vitamin D-binding protein-derived
macrophage-activating factor on human breast cancer cells.
Anticancer Res, 2012; 32(1):45-52. 
2 Thyer L et al: A novel role for a major component of the
vitamin D axis: vitamin D binding protein-derived
macrophage activating factor induces human breast cancer
cell apoptosis through stimulation of macrophages. Nutrients
2013; 5(7):2577-2589. 
3 Gregory KJ et al: Vitamin D binding protein-macrophage
activating factor directly inhibits proliferation, migration,
and uPAR expression of prostate cancer cells. PLoS One
2010; 5(10):e13428. 
4 Thyer L et al: Therapeutic effects of highly purified de-
glycosylated GcMAF in the immunotherapy of patients with
chronic diseases. Am J Immunol 2013; 9(3):78-84. 
5 Yamamoto Net al: Immunotherapy for prostate cancer with
gc protein derived macrophage-activating factor OA-
GcMAF. Trans Oncol 2008; 1:65-72 
6 Ruggerio M et al: Oleic acid, deglycosylated vitamin D-
binding protein, nitric oxide: a molecular triad made lethal
to cancer. Anticancer Res 2014; 34: 3569-3578.
605
SENESCENCE LINKED INFLAMMATION,
REPLICATION STRESS, FRAGILE SITES AND DNA
METHYLATION CHANGES IN SPORADIC 
BREAST AND PROSTATE CANCER.
Steven Smith
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Hypermethylation tends to occur near fragile sites in cancer
(1). Persistent daughter strand gaps near fragile sites appear to
play a key role in this process in human breast and prostate
cancer. Like reactive oxygen species, 5-Azacytidine and its
primary breakdown product deoxyriboguanylurea produce
replication stress that induces fragile sites (2). The recently
elucidated repair processes invoked by replication stress at
fragile sites involving Mus81-EME and ERRC1 (3) coupled
with the enzymology of DNA methytransferases provide a
clear model for methylation change at these sites during
carcinogenesis. Evidence obtained with nanotechnology
strongly suggests that an M1 inflammation is present at the
invasive edges of human prostate tumors and that it produces
persistent replication stress at this interface through the
production of reactive oxygen species. Persistent daughter
strand gaps at a hot spot for DNA methylation near Fragile
site 11J in human breast and prostate tumor specimens provide
additional evidence for inflammation’s role in epigenetic
changes seen in human tumors. The data will be discussed in
terms the possible link between the Senescence Associated
Secretory Phenotype (SASP) (4), the Senescence Messaging
Secretome (SMS) (5) and Proliferative Inflammatory Atrophy
(6) seen in prostate cancer. 
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